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Abstract
Mast cells are best known for their role in allergic reactions, where aggregation of FceRI leads to the release of mast cell
mediators causing allergic symptoms. The activation also induces a survival program in the cells, i.e., activation-induced
mast cell survival. The aim of the present study was to investigate how the activation-induced survival is mediated. Cord
blood-derived mast cells and the mast cell line LAD-2 were activated through FceRI crosslinking, with or without addition of
chemicals that inhibit the activity or expression of selected Bcl-2 family members (ABT-737; roscovitine). Cell viability was
assessed using staining and flow cytometry. The expression and function of Bcl-2 family members BFL-1 and MCL-1 were
investigated using real-time quantitative PCR and siRNA treatment. The mast cell expression of Bfl-1 was investigated in skin
biopsies. FceRI crosslinking promotes activation-induced survival of human mast cells and this is associated with an
upregulation of the anti-apoptotic Bcl-2 family member Bfl-1. ABT-737 alone or in combination with roscovitine decreases
viability of human mast cells although activation-induced survival is sustained, indicating a minor role for Bcl-XL, Bcl-2, Bcl-w
and Mcl-1. Reducing BFL-1 but not MCL-1 levels by siRNA inhibited activation-induced mast cell survival. We also
demonstrate that mast cell expression of Bfl-1 is elevated in birch-pollen-provocated skin and in lesions of atopic dermatitis
and psoriasis patients. Taken together, our results highlight Bfl-1 as a major effector in activation-induced human mast cell
survival.
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Introduction
Mast cells are known to be central effectors and regulators in
allergic diseases. When a multivalent antigen binds to IgE
occupying the high affinity receptor for IgE (FceRI), receptor
aggregation and subsequent mast cell activation occurs. This result
in mast cell degranulation, changes in gene expression, and the
release of inflammatory mediators causing the symptoms associ-
ated with allergic reactions [1,2,3]. In addition, the mast cell has
the ability to survive the degranulation process, regranulate, and
be activated again, which perpetuates the allergic reaction [4,5].
One important question in mast cell biology is how mast cells
survive during this degranulation – regranulation process.
It has previously been demonstrated that the aggregation of
FceRI can result in increased survival of mast cells (activation-
induced survival) [6,7,8,9]. Upon crosslinking of FceRI (IgECL)
murine mast cells upregulate anti-apoptotic Bcl-2 family member
A1 and bcl-XL and also to a lesser extent bcl-2 at the mRNA level
[8,10,11]. We have previously shown that mouse mast cells
deficient in A1 do not exhibit activation-induced survival upon
IgECL [8], suggesting that A1 is essential for this process in mouse.
Similarly, the human homologue of A1, BFL-1, is upregulated in
human mast cells upon IgECL [12] together with anti-apoptotic
Bcl-2 family member MCL-1 [12,13]. These observations provide
a possible explanation for IgE-mediated activation-induced mast
cell survival. Furthermore, FccRI crosslinking also induces BFL-1
upregulation and activation-induced human mast cell survival
[14], further suggesting that activation through these Fc-receptors
contributes to mast cell survival.
Here we describe that Bfl-1 is a mediator of activation-induced
human mast cell survival as demonstrated by siRNA experiments.
We also demonstrate that activation-induced mast cell survival is
sustained when the anti-apoptotic proteins Bcl-XL, Bcl-2, Bcl-W
and Mcl-1 are targeted using inhibitors, indicating a minor role for
the targeted anti-apoptotic Bcl-2 family members. Furthermore,
Bfl-1 is upregulated in mast cells in various skin inflammatory
models. Therefore, the observations highlight Bfl-1 as a potential
target for treatment of allergic and inflammatory diseases.
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IgECL promotes activation-induced survival in cytokine
deprived human mast cells
IgECL has been shown to promote survival of mast cells
cultured in the absence of their required growth factors [7,8,9].
We therefore investigated the survival capacity of human cytokine-
deprived cord blood-derived mast cells (CBMCs) and the human
mast cell line LAD-2 following IgECL using a fixed concentration
of human IgE (1 mg/ml) and 0.2, 2 or 20 mg/ml of anti-human
IgE. The results show that IgECL resulted in prolonged survival of
cytokine-deprived CBMCs for all anti-human IgE concentrations
tested (Fig. 1A). Also LAD-2 cells responded with an increased
survival after activation with 2 mg/ml of anti-human IgE (Fig. 1B).
For further studies the concentration of 2 mg/ml of anti-human
IgE was chosen since the results indicated that this concentration is
superior (P=0.039 and 0.031 respectively) as compared to 0.2 and
20 mg/ml for achieving activation-induced survival of CBMCs and
LAD-2 cells.
Activation-induced mast cell survival is not dependent
on Bcl-2, Bcl-XL, Bcl-w or Mcl-1
The family of pro-survival Bcl-2 proteins in humans consists of
Bcl-2, Bcl-XL, Bcl-W, A1/Bfl-1, Bcl-B and Mcl-1. The activation-
induced survival following IgECL is a complex process where Bcl-
XL, Bfl-1 and Mcl-1 has been demonstrated to be induced in
human mast cells, and hence have a possible role in activation-
induced mast cell survival [8,13]. To evaluate the role of Bcl-2,
Bcl-XL, Bcl-W and Mcl-1 we used the BH3-only mimetic ABT-
737 alone or in combination with roscovitine. ABT-737 is a small
molecular inhibitor mimicking the binding of the BH3 domain of
the pro-apoptotic protein Bad [15]. It binds with high affinity to
the anti-apoptotic proteins Bcl-XL, Bcl-2 and Bcl-W but not Mcl-
1, Bcl-B or A1/Bfl-1. The cyclin-dependent kinase (CDK)
inhibitor roscovitine has been reported to down-regulate the
anti-apoptotic protein Mcl-1 [16,17,18,19]. The concentrations of
ABT-737 and roscovitine used were chosen based on dose-
response data (not shown) and with the purpose of inducing a
degree of apoptosis similar to cytokine deprivation in our system.
Upon treating CBMCs with 0.5 mM ABT-737, mast cell
viability decreased by approximately 10% and combination of
0.5 mM ABT-737 and 5 mM roscovitine decreased this viability
even further by another 20% (Fig. 2A). Decreased viability could
also be observed for LAD-2 cells where the viability was decreased
by approximately 25% in response to ABT-737 or ABT-737 in
combination with roscovitine (Fig. 2B). The results show that
IgECL resulted in prolonged survival of both ABT-737 and ABT-
737/Roscovitine-treated CBMCs and LAD-2 cells (Fig. 2A–B).
These results demonstrate that the ability to induce survival is
sustained in an experimental setting where Bcl-2, Bcl-XL, Bcl-W
and Mcl-1 are inhibited, and suggest that one of the remaining
pro-survival Bcl-2 family members (i.e. Bfl-1 and Bcl-B) was
responsible for the activation-induced survival response. Since
mice lack an obvious ortholog of Bcl-B, we focused on Bfl-1, the
human ortholog of A1 which was shown to be essential for murine
activation-induced mast cell survival [8].
siRNA targeting BFL-1 inhibits activation-induced survival
of human mast cells
Having demonstrated a minor role of Bcl-XL, Bcl-2, Bcl-W and
possibly also Mcl-1 we next examined how inhibition of BFL-1
affects activation-induced survival of CBMC and LAD-2 cells. To
inhibit gene expression, cells were electroporated using siRNA
oligonucleotides targeting BFL-1, MCL-1 or non-targeting siRNA.
Activation-induced upregulation of both BFL-1 and MCL-1 at the
mRNA level following IgECL were abolished by siRNA
treatment, as demonstrated by quantative PCR (Fig. 3A and C).
The expression of BCL-2, BCL-XL,o rC-KIT was not affected (data
not shown). In contrast, activation-induced survival was dimin-
ished by BFL-1 targeting siRNA but not by MCL-1 targeting
siRNA (Fig. 3B and D). We could also demonstrate, by
immunohistochemical staining, Bfl-1 to be down-regulated on
the protein level in CBMC and LAD-2 cells by BFL-1 siRNA
treatment as compared to non-targeting siRNA (fig. 3E). Taken
together our results demonstrate the critical role of Bfl-1 in
prolonging the survival of cytokine-deprived human mast cells
after IgECL and support our hypothesis that Bfl-1 is a major
survival factor promoting activation-induced survival. Mcl-1 by
comparison, seems to play a minor role in activation-induced mast
cell survival, even though IgECL induces Mcl-1 expression.
Bfl-1 is expressed in skin tissue mast cells and is increased
under inflammatory conditions
CBMCs as well as LAD-2 cells express tryptase and chymase
(data not shown) [20,21,22] exhibiting a human MCTC pheno-
type, which is the dominating phenotype in connective tissues, e.g.
the skin [23]. To examine if Bfl-1 is regulated in tissue mast cells,
we therefore used a doublestaining technique on skin biopsies as
previously described [24]. An enzymatical staining followed by an
Figure 1. IgECL-induced survival of human mast cells. (A). CBMC upon IgECL. (B) LAD-2 cells upon IgECL. Cells were sensitized with 1 mg/mL of
IgE overnight before cytokine-deprived and challenged with anti-IgE. After 24 hrs the cell viability was enumerated using trypan blue exclusion.
N=3–4.
doi:10.1371/journal.pone.0039117.g001
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strated that Bfl-1 is expressed in skin tissue mast cells (Fig. 4).
To examine if Bfl-1 is regulated in skin mast cells in vivo we
performed allergen challenge on birch-pollen allergic patients.
Skin biopsies were obtained 24 h following challenge with pollen
allergen or diluent. A significant increase in mast cell Bfl-1
expression in the biopsies from allergen provoked skin compared
with control was observed (Fig. 5a). We could not observe any
significant changes in mast cell number (data not shown). Thus,
IgE-receptor activated human mast cells upregulate Bfl-1 upon
allergic provocation in vivo.
Although mast cells are perhaps best known for their
involvement in allergic diseases, growing evidence also suggest
that mast cells are involved in inflammatory mechanisms of
chronic skin diseases. Atopic dermatitis (AD), psoriasis (PSO), and
basal cell carcinoma (BCC) are chronic cutaneous inflammatory
diseases where the number of mast cells is higher to varying extents
in lesional compared with nonlesional skin [24,25]. We therefore
investigated if expression of the pro-survival protein Bfl-1 was
increased concomitant to increased mast cell numbers in the
lesional skin. A significant increase in mast cell Bfl-1 expression in
the lesional skin of AD and PSO patients compared with
nonlesional skin from the same patients was observed (Fig. 5b).
In addition, Bfl-1 was increased in the lesional BCC skin in every
case, though statistical significance was not reached (p=0.078).
Discussion
In the present study we provide strong evidence that activation-
induced human mast cell survival is dependent on the expression
of Bfl-1 and that Bfl-1 is induced in skin mast cells in vivo.
We have previously demonstrated that, in the mouse, mRNA
levels for the anti-apoptotic Bcl-2 family member A1 are increased
following IgECL and that mast cells lacking A1 do not gain a
survival advantage from IgECL [8]. Similarly, our results using
quantative PCR confirm that BFL-1 is upregulated at mRNA level
following IgECL in human mast cells ([12] and this study).
However, activation-induced mast cell survival following IgECL is
a complex process where also other anti-apoptotic Bcl-2 family
members apart from A1/Bfl-1 are regulated. In the murine
system, anti-apoptotic Bcl-XL is increased following IgECL [8,26]
and in human mast cells Mcl-1 [12,13] is upregulated. Our results
using the BH3 mimetic compound ABT-737 suggests a minor role
of anti-apoptotic Bcl-XL, Bcl-2 and Bcl-W in human mast cell
survival following IgECL. Furthermore, the use of ABT-737
combined with roscovitine also implicates a minor role for Mcl-1
in activation-induced survival following IgECL. In contrast, mast
cell survival was impaired by BFL-1 (but not MCL-1) knockdown
using siRNA. Altogether, our results establish the importance of
BFL-1 for activation-induced survival of human mast cells in vitro.
To examine if Bfl-1 is regulated in activated mast cells in vivo we
used human skin biopsies from birch-pollen allergic patients. We
found a significant increase in mast cell Bfl-1 expression in allergen
provocated skin. Although we could not detect a statistically
significant change in mast cell numbers after 24 hours following
allergen challenge it seems plausible that an increased mast cell
Bfl-1 expression over time would lead to an increase in mast cell
numbers. Thus, both our in vivo and in vitro findings suggest that
activated mast cells upregulate Bfl-1 upon allergic provocation,
highlighting Bfl-1 as a potential target for treatment of allergic
diseases.
In addition, we also found a significant increase in mast cell Bfl-
1 expression in lesional skin of AD and PSO patients compared
with nonlesional skin from the same patients. FceRI-dependent
activation of mast cells is not commonly associated with these
diseases, but it has been reported that in IFN-c-rich psoriatic skin
[27] mast cells express FccRI [28]. Interestingly, we have
previously shown that also FccRI crosslinking of in vitro-generated
human mast cells induce BFL-1 upregulation and activation-
induced mast cell survival [14]. Thus, we believe that activation-
induced mast cell survival is an Fc-mediated mechanism, as we
have not been able to observe this BFL-1 upregulation and
activation-induced survival for other types of mast cell stimuli, e.g.
through adenosine receptors [11] or compound 48/80 [8]. Since
our findings suggest that activation-induced mast cell survival is
dependent on the upregulation of BFL-1 and that there is an
increase of mast cell Bfl-1 expression in lesional skin of AD and
PSO patients, this could be an important explanation to increased
mast cell numbers seen in AD, PSO and BCC. Still, the role of
Figure 2. Activation-induced mast cell survival following IgECL in presence of ABT-737 and roscovitine. (A) CBMC treated with 0.5 mM
ABT-737 alone or in combination with 5 mM roscovitine following IgECL. N=6–3. (B) LAD-2 treated with 0.5 mM ABT-737 alone or in combination with
5 mM roscovitine following IgECL. N=3 Viability was assessed after 24 hrs using propidium iodide plus FITC-conjugated Annexin V. Change in
viability is expressed as percentage viable cells after treatment deducted from untreated cells. ABT-737 = ABT, roscovitine = rosc.
doi:10.1371/journal.pone.0039117.g002
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have in mast cell survival in AD, PSO and BCC remains to be
determined.
Altogether, the results reported here suggest that Bfl-1 is among
the contributors to survival of mast cells, raising the possibility that
agents neutralizing this Bcl-2 family member could find a role in
the treatment of a wide variety of allergic and chronic
inflammatory diseases.
Figure 3. siRNA targeting BFL-1 but not MCL-1 diminishes activation-induced survival of human mast cells. (A) The upregulation of BFL-
1 and MCL-1 following IgECL in CBMCs is abolished following targeted siRNA treatment as verified 30 hours post-transfection by quantative PCR. Cells
were transfected with 100 nM siRNA, sensitized with 1 mg/mL of IgE and challenged with 2 mg/mL anti-IgE before expression was determined. Data
correspond to one representative experiment using one donor. Similar result was obtained for another donor. (B) BFL-1 but not MCL-1 siRNA treated
CBMCs show decreased survival upon IgECL compared to control siRNA treated cells. Cells were transfected, sensitized with 1 mg/mL of IgE and
24 hours post-transfection cytokine-deprived and challenged with 2 mg/mL anti-IgE before being enumerated 24 hours later using the vital dye
trypan blue. N=6. (C) The upregulation of BFL-1 and MCL-1 following IgECL in LAD-2 cells is abolished following targeted siRNA treatment as
described above. (D) BFL-1 but not MCL-1 siRNA treated LAD-2 cells show decreased survival upon IgECL compared to control siRNA treated cells.
N=4. Change in viability is percentage viable cytokine-deprived cells deducted from viable cytokine-deprived cells following IgECL. (E) Bfl-1 is down-
regulated in LAD-2 cells following siRNA treatment targeting BFL-1 as compared to control siRNA in immunohistochemical stainings for Bfl-1
expression.
doi:10.1371/journal.pone.0039117.g003
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Ethics statement
All patients provided written informed consent. The regional
ethics review board for medical research in Gothenburg, Sweden
and the etical committee of Kuopio University Hospital, Kuopio,
Finland approved the studies.
Cell cultures
Cord blood-derived mast cells (CBMCs) were derived in
supplemented StemPro-34 SFM medium (Invitrogen Corp.,
Carlsbad, CA, USA) including 100 ng/mL recombinant human
SCF (hSCF, Peprotech EC Ltd, London, UK) and 10 ng/mL
human IL-6 (Peprotech EC Ltd) as previously described [12]. The
human mast cell line LAD-2 (kindly provided by Drs. A.
Kirshenbaum and D. Metcalfe, NIH, Bethesda, MD, USA) [22]
was maintained in supplemented StemPro-34 SFM medium with
100 ng/mL hSCF.
Mast cell activation
Cells (10
6 cells/mL) were incubated with 1 mg/mL IgE
(AG30P, Millipore, Billerica, MA, USA) overnight, washed with
PBS, and activated with 0.2, 2 or 20 mg/mL anti-human IgE
(Sigma, St. Louis, MO, USA) for 24 hours in medium deprived of
cytokines. For inhibition studies, 0.5 mM ABT-737 (provided by
Abbott laboratories) was added at the time of activation, whereas
5 mM roscovitine (Sigma) was added two hours prior activation.
Cell survival assays
Enumeration of viable cells was performed by trypan blue
exclusion or propidium iodide (PI, 2 mg/mL) and FITC-conju-
gated annexin V (0.3 mg/mL) analyzed by FACScan (Becton
Dickinson, Franklin Lakes, NJ, USA).
RNA preparation and real-time quantitative PCR
RNA was extracted using TriPure isolation reagent (Roche
Diagnostics) according to the manufacturer’s protocol. cDNA was
synthesised using a First Strand cDNA Synthesis Kit (Roche
Diagnosticss) and amplified using 1xSYBR Green PCR master
mix (Applied Biosystems, Foster City, CA, USA) and 700 nM of
Figure 4. Bfl-1 is expressed in skin tissue mast cells. An
enzymatical staining for tryptase followed by an immunohistochemical
staining of Bfl-1 (upper panel) and was performed on atopic dermatitis
(AD) lesional skin. Isotype control staining following tryptase staining
(lower panel).
doi:10.1371/journal.pone.0039117.g004
Figure 5. Elevated Bfl-1 expression upon allergen provocation in birch-pollen allergic patients (A) and in lesions of atopic
dermatitis (AD) and psoriasis patients (PSO) (B). An enzymatical staining for tryptase followed by an immunohistochemical staining of Bfl-1
was performed. The results are presented as the percentage of mast cells expressing Bfl-1.
doi:10.1371/journal.pone.0039117.g005
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comparative DCt method in which human gyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used for normalization.
Listed 59 to 39, primer sequences were as follows: BFL-1 forward,
AAATGTTGCGTTCTCAGTCC; BFL-1 reverse,
AGCCTCCGTTTTGCCTTATC; MCL-1 forward,
TTACCGCGTTTCTTTTGAGG; MCL-1 reverse CACTTCT-
CACTTCCGCTTCC; GAPDH forward, TCGGAGTCAACG-
GAT; GAPDH reverse, CTCCGACGCCTGCTT.
siRNA-mediated inhibition of BFL-1 and MCL-1 gene
expression
CBMC and LAD-2 cells were transfected using Human MCL1
SMARTpool siRNA Reagent, BCL2A1 SMARTpool siRNA
Reagent or human ON-TARGETplus Non-targeting siRNA
(Dharmacon Inc., Lafayette, CO, USA). 100 nM siRNA was
introduced using a Nucleoporator (nucleofector kit VPI-1002;
program X-001 (Amaxa AG, Cologne, Germany)). 24 hours post-
transfection, the dead cell removal kit MACS (Miltenyi Biotec,
Bergisch Gladbach, Germany) was used before anti-human IgE
was added as described previously. Inhibition of BFL-1 and MCL-1
expression was verified by real-time quantitative PCR 30 hours
post-transfection.
Antibody generation and characterization
The anti-Bfl-1 serum (SB-50) was generated in rabbits using
recombinant Bfl-1 protein. Bfl1 was produced as GST fusion
protein from pGEX vectors using Escherichia coli BL21 (DE3) as
the host strain. The protein purification method has been
described previously [29]. New Zealand white female rabbits
were injected subcutaneously with a mixture of recombinant
protein (0.1 to 0.25 mg protein/immunization) and 0.5 ml
Freund’s complete adjuvant (dose divided over 10 injection sites),
boosted three times at weekly intervals, followed by another 3 to
20 boostings at monthly intervals with recombinant protein in
Freund’s incomplete adjuvant, collecting blood at 1 to 3 weeks
after each boosting to obtain serum.
Detection of mast cell Bfl-1 expression
Bfl-1 expression in IgECL-activated CBMC and LAD-2 cells
following siRNA treatment was investigated using an immunohis-
tochemical staining of Bfl-1. Slides were immunohistochemically
stained with an anti-Bfl-1 polyclonal rabbit antibody and the
EnVision system and the 3-amino-9-etyhlcarbazole (AEC) method
(Sigma) were performed according to the manufacturer’s instruc-
tions (Dakocytomation, Carpinteria, CA, USA).
Bfl-1 expression in mast cells in skin inflammatory conditions
was investigated in a blinded fashion using a sequential double-
staining, combining an enzymatical staining for tryptase with the
immunohistochemical staining of Bfl-1 [24,30]. Tryptase contain-
ing cells were visualized using 1 mM Z-Gly-Pro-Arg-4-methoxy-2-
naphthylamide (MNA) (Bachem, Bubendorf, Switzerland) and
Fast Garnet GBC (Sigma) and the sections were immunohisto-
chemically stained for Bfl-1 as described above. The mast cells
were counted in a total area of 0.2–0.4 mm
2 just beneath the
epidermis.
Six birch-allergic patients with a clinical history of birch pollen-
induced rhinoconjunctivitis were included in the study. The birch
allergy was confirmed by positive skin prick test: 3 mm and serum-
specific IgE antibodies to birch: class 2 (CAP system, Phadia,
Uppsala, Sweden). Allergen challenge was performed and biopsies
were collected outside birch pollen season. 50 SQ-U birch pollen
allergen extracts (AquagenH SQ Betula verrucosa; ALK-Abello,
Hørsholm, Denmark) was injected intracutaneously in the
forearm. Albumin diluent (AquagenH SQ) was injected in the
opposite forearm as a negative control. Skin biopsies were taken
24 h following challenge using a 3 mm disposable punch, under
local anaesthesia with XylocainH (Astra AB, So ¨derta ¨lje, Sweden).
Samples were snap frozen, embedded immediately in TissueTek
(Zoeterwoude, Netherlands) OCT medium and stored at 270uC.
For staining, 6 mm thick sections were cut by cryostat (Leica
CM1800, Nusstoch bei Heidelberg, Germany).
We also included three skin biopsy series from patients with
atopic dermatitis, psoriasis, and basal cell carcinoma. The patients
had not received any effective internal or UV-light treatment
before biopsing. Punch biopsies (4 mm) were taken from untreated
lesional skin and from healthy-looking skin at least 2 cm apart
from the lesions. The biopsies were immediately embedded in
OCT compound (Miles Scientific, Naperville, IL, USA) and
frozen for preparation of 5-mm-thick cryosections [24,30].
Statistics
All data, unless otherwise stated, are presented as the mean 6
SEM. The differences among different groups were determined by
the Student’s t test. P,0.05 was considered significant.
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